Carcinoma in situ of penis

CD2_INSITU_PENIS_EXALLC

No definition available.

Endpoint definition

↥

Endpoint definition steps	FinnGen
Phenotype data
1. Apply sex-specific rule only males	-
2. Check conditions not C3_PENIS	-
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — D07.4& Hospital discharge: ICD-9 — 2335 Cause of death: ICD-10 — D07.4& Cause of death: ICD-9 — 2335 Cancer registry: Topography ICD-O-3 — C60 Cancer registry: Morphology ICD-O-3 — ANY Cancer registry: Behaviour codes — 2 3 out of 7 registries used, show all original rules.	-
4. Check minimum number of events None	-
5. Include endpoints None	-
6. Filter based on genotype QC (FinnGen only) None	-

Control definitions (FinnGen only)

Control exclude: C3_CANCER, C3_CANCER_WIDE

Extra metadata

Level in the ICD hierarchy: 3
First used in FinnGen datafreeze: DF9
Parent code in ICD-10: D07
Name in latin: Carcinoma in situ vesicae urinariae

NAME	CD2_INSITU_PENIS_EXALLC
CONTROL_EXCLUDE	C3_CANCER\|C3_CANCER_WIDE
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX	1
INCLUDE
PRE_CONDITIONS
CONDITIONS	!C3_PENIS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	D074
HD_ICD_9	2335
HD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	D074
COD_ICD_9	2335
COD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO	C60
CANC_TOPO_EXCL
CANC_MORPH	ANY
CANC_MORPH_EXCL
CANC_BEHAV	2

Similar endpoints

↥

List of similar endpoints to Carcinoma in situ of penis based on the number of shared cases.

Similar with more cases:

Similar with less cases:

Carcinoma in situ of penis

Case counts by codes

↥

FinnGen case counts by registry codes:

No upset plot: script not run.

No upset table: script not run.

Summary Statistics

↥

-FinRegistry-

Key figures

	All	Female	Male
Number of individuals
Whole population	-	-	-
Only index persons	-	-	-
Unadjusted period prevalence (%)
Whole population	-	-	-
Only index persons	-	-	-
Median age at first event (years)
Whole population	-	-	-
Only index persons	-	-	-

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	54	-	54
Unadjusted period prevalence (%)	0.02	-	0.02
Median age at first event (years)	66.19	-	66.19

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

No data

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

No data available

LabWAS

↥

(ID) Name

N Cases

N Controls

-log₁₀(p)

cases

controls

cases

controls

unit

-log₁₀(p)

N cases

N controls

(40768443) Skin Pathology biopsy report

13.46

13.77

1.6

1.2

—

(4035726)

11.91

11.23

1.7

1.1

—

(40768804) Tissue Pathology biopsy report

6.31

10.53

3.6

1.4

—

(3002256) Pathology report gross observation

7.31

8.57

1.5

1.1

—

(42870588) Differential panel, method unspecified - Blood

126

3.81

5.55

13.2

5.5

—

(3042936) Bacteria identified in Isolate by Culture

4.08

5.42

1.7

2.5

—

(40758558) Short blood count panel - Blood

3.61

4.67

14.1

5.2

—

(3008909) Norovirus RNA [Presence] in Stool by NAA with probe detection

13.13

4.41

1.6

1.0

—

(3000494) Fungus identified in Specimen by Culture

3.85

4.19

1.3

1.9

—

(3051552) Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection

4.89

4.08

2.0

1.2

—

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

147

2.88

3.55

4.9

4.8

—

(3044640) Blood type and Crossmatch panel - Blood

102

2.95

3.48

3.8

2.5

—

(36304419) Bacteria [Presence] in Urine

104

2.88

3.34

4.5

2.3

—

(3049717) Cytology report of Urine Cyto stain

7.12

3.30

3.0

1.5

—

(3029879) Epithelial cells.squamous [#/volume] in Urine by Automated count

3.08

3.28

4.0

2.5

0.8

0.9

e6/l

0.08

(3030306) Epithelial cells.non-squamous [#/volume] in Urine by Automated count

3.08

3.28

3.9

2.4

0.2

0.9

e6/l

2.06

(3006315) Basophils [#/volume] in Blood

197

2.74

3.17

9.6

5.2

0.0

e9/l

0.24

171

(3001604) Monocytes [#/volume] in Blood

197

2.74

3.17

9.6

5.2

0.7

0.6

e9/l

0.54

170

(36031861) Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection

3.86

3.08

2.3

1.5

—

(3013115) Eosinophils [#/volume] in Blood

203

2.61

2.89

10.8

5.3

0.2

e9/l

0.16

176

(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection

2.87

2.81

3.0

1.7

—

(3014162) Mycobacterium tuberculosis DNA [Presence] in Specimen by NAA with probe detection

5.19

2.69

1.7

4.5

—

(3022948) Iron [Moles/volume] in Serum or Plasma

2.86

2.68

3.4

2.8

14.7

12.1

umol/l

0.55

(46236098) ABO and Rh group [Type] in Blood by Confirmatory method

2.72

2.66

4.2

2.5

—

(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count

148

2.46

2.62

5.0

2.7

—

(46235355) HIV 1 and 2 tests - Meaningful Use set

3.07

2.56

1.4

1.8

—

(3023368) Bacteria identified in Blood by Culture

133

2.45

2.55

7.5

4.1

—

(40763571) Iron/Transferrin [Ratio] in Serum or Plasma

2.80

2.34

3.7

2.9

28.7

24.5

0.32

(3021589) Normoblasts [#/volume] in Blood

181

2.30

12.9

8.8

0.0

e9/l

0.00

146

(43054903) Holo-transcobalamin II [Moles/volume] in Serum

180

2.15

1.99

2.4

1.9

95.6

86.0

pmol/l

0.36

106

(3005702) Mycobacterium sp identified in Specimen by Organism specific culture

4.47

1.86

1.2

1.3

—

(36305247) Microscopic observation [Identifier] in Isolate by Gram stain

4.47

1.86

1.0

1.3

—

(3016251) Hemoglobin.gastrointestinal [Presence] in Stool

3.19

1.79

2.4

2.0

—

(3035995) Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma

316

2.24

1.72

15.1

5.4

89.4

71.8

u/l

1.38

292

(3000492) Spirometry study

2.63

1.72

2.3

1.4

—

(3019800) Troponin T.cardiac [Mass/volume] in Serum or Plasma

189

2.00

1.67

3.8

4.1

34.3

53.7

ng/l

0.52

145

(3044254) Respiratory syncytial virus RNA [Presence] in Specimen by NAA with probe detection

3.82

1.65

3.6

1.6

—

(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection

2.40

1.57

2.1

1.7

—

(46235759) Influenza virus B RNA [Presence] in Nasopharynx by NAA with probe detection

3.56

1.56

4.8

1.7

—

(1761868) Lipid panel - Serum or Plasma

149

0.46

1.29

3.1

3.4

—

(3000850) Epithelial cells [#/volume] in Urine

2.01

1.28

2.7

1.9

4.6

2.7

e6/l

0.43

(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection

2.23

1.26

2.2

1.6

—

(3037467) Urinalysis macro (dipstick) panel - Urine

261

1.82

1.25

6.6

3.6

—

(3009542) Hematocrit [Volume Fraction] of Blood

356

2.02

1.23

37.5

15.8

40.5

41.2

0.31

236

(3021337) Troponin I.cardiac [Mass/volume] in Serum or Plasma

1.90

1.20

3.1

3.6

31.9

250.6

ng/l

1.37

(586526) SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection

2.36

1.13

2.0

1.4

—

(40764999) Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)

385

2.01

1.11

27.9

12.3

78.5

76.5

ml/min/173m2

0.23

310

(40768797) Stomach Pathology biopsy report

2.09

1.09

1.3

1.1

—

(3007164) IgA [Mass/volume] in Serum or Plasma

2.01

1.08

1.7

1.2

2.1

2.6

g/l

—

(40762366) Oxygen capacity [Volume Fraction] in Arterial blood

2.40

1.05

8.6

41.5

—

(3021879) Hepatitis B virus core Ab [Presence] in Serum

2.40

1.05

3.0

1.4

—

(3003694) ABO and Rh group [Type] in Blood

1.82

1.04

1.2

1.3

—

(3017143) Hepatitis C virus Ab [Presence] in Serum

2.15

1.04

3.7

1.6

—

(3019902) Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture

2.08

1.01

4.1

3.7

—

(3022145) Colonoscopy Study observation

2.08

1.01

1.7

1.2

—

(21494755) Public health laboratory ask at order entry panel

0.00

1.01

0.0

1.4

—

(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection

223

1.65

0.97

3.3

2.3

—

(3009343) pH of Capillary blood

2.28

0.95

9.2

4.0

—

(3020460) C reactive protein [Mass/volume] in Serum or Plasma

417

1.98

0.92

33.4

13.9

40.0

27.5

mg/l

0.74

328

(3007853) Bacteria identified in Skin by Aerobe culture

1.82

0.85

1.5

2.2

—

(3000991) Gas panel - Venous blood

1.82

0.85

9.1

11.1

—

(3013603) Prostate specific Ag [Mass/volume] in Serum or Plasma

331

1.64

0.82

5.7

3.9

3.7

2.1

ug/l

0.30

294

(4034850)

0.00

0.81

0.0

16.6

—

(3011397) Hemoglobin [Presence] in Urine by Test strip

1.68

0.79

4.6

2.9

—

(3022313) Gas panel - Capillary blood

2.29

0.78

9.6

3.7

—

(3003510) Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection

2.01

0.72

1.2

1.9

—

(3050449) Albumin [Mass/time] in Urine collected for unspecified duration

0.00

0.62

0.0

2.0

—

106.6

—

(3019284) Hepatitis B virus surface Ag [Presence] in Serum

1.86

0.61

1.8

1.6

—

(4010399)

1.70

0.58

1.0

1.3

—

(3019050) Tissue transglutaminase IgA Ab [Units/volume] in Serum

1.51

0.56

1.3

1.2

—

0.9

—

(3044889) 12 lead EKG panel

308

1.39

0.47

4.6

4.4

—

(3003396) Base excess in Arterial blood by calculation

1.47

0.45

6.8

19.6

-0.3

1.0

mmol/l

—

(46236952) Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD)

1.52

0.41

2.6

2.2

—

61.4

—

(3032080) INR in Blood by Coagulation assay

183

1.34

0.41

9.2

11.9

1.5

1.4

inr

—

(3026008) Bacteria identified in Urine by Culture

1.41

0.40

3.6

2.5

—

(40761535) Cells panel - Urine sediment

1.52

0.37

8.2

2.5

—

(3003031) Transferrin.carbohydrate deficient.disialo/Transferrin.total in Serum or Plasma

1.37

0.32

1.9

2.0

1.5

2.0

—

(3019225) pH of Specimen

1.31

0.23

8.4

3.5

—

(3012501) Base excess in Blood by calculation

0.00

0.21

0.0

2.8

—

2.6

—

(3038515) Glucose [Moles/volume] in Venous blood

0.00

0.21

0.0

4.4

—

7.3

—

(3008037) Lactate [Moles/volume] in Venous blood

0.00

0.21

0.0

4.2

—

2.0

—

(4094501)

0.00

0.20

0.0

1.1

—

(3001784) Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma

259

1.17

0.16

4.2

3.5

16.6

24.8

1.88

115

(40761511) CBC panel - Blood by Automated count

436

1.19

0.14

25.8

13.5

—

(3015736) pH of Urine

154

1.15

0.12

4.2

3.0

—

(3013512) EKG study

140

1.10

0.05

7.1

4.2

—

(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip

150

0.91

0.05

4.2

3.4

—

(3041096) Erythrocytes [Presence] in Urine by Automated

1.03

0.00

2.6

3.3

—

(3033705) Calcium.ionized [Moles/volume] in Venous blood

0.00

0.0

1.8

—

(3018301) Testosterone Free [Moles/volume] in Serum or Plasma

0.00

0.0

1.1

—

(3010566) Parathyrin.intact [Moles/volume] in Serum or Plasma

0.00

0.0

5.3

—

(3041354) Potassium [Moles/volume] in Venous blood

0.00

0.0

1.8

—

4.1

—

(3035285) Chloride [Moles/volume] in Venous blood

0.00

0.0

1.8

—

105.4

—

(3012220) Varicella zoster virus IgM Ab [Presence] in Serum by Immunoassay

0.00

0.0

1.0

—

(40760892) CBC W Ordered Manual Differential panel - Blood

0.88

0.00

5.4

4.3

—

(3021788) Differential panel - Synovial fluid

0.00

0.0

1.0

—

(3004383) Neutrophil cytoplasmic Ab.classic [Titer] in Serum by Immunofluorescence

0.00

0.0

1.3

—

(3016650) Hepatitis A virus Ab [Presence] in Serum

0.00

0.0

1.0

—

(3044927) Protein electrophoresis panel - Urine

0.00

0.0

1.2

—

(3042631) Mycobacterium sp identified in Specimen

0.00

0.0

2.0

—

(3014973) Borrelia burgdorferi IgM Ab [Units/volume] in Cerebral spinal fluid

0.00

0.0

1.2

—

(3046294) Neutrophil cytoplasmic Ab.classic [Titer] in Serum

0.00

0.0

1.2

—

(3031478) Chlamydophila pneumoniae DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.1

—

(3045783) Sodium and Potassium panel [Moles/volume] - Serum or Plasma

0.90

0.00

11.3

8.4

—

(3023150) Myeloperoxidase Ab [Units/volume] in Serum

0.00

0.0

2.8

—

(3005785) Creatine kinase.MB [Mass/volume] in Serum or Plasma

0.88

0.00

2.8

2.9

2.1

7.3

ug/l

—

(3013327) Hepatitis A virus IgM Ab [Presence] in Serum

0.00

0.0

1.0

—

(3014148) Varicella zoster virus Ab [Titer] in Serum

0.00

0.0

1.0

—

(3011371) Neisseria gonorrhoeae DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

2.8

—

(3002032) Base excess in Venous blood by calculation

1.02

0.00

10.0

3.6

0.6

1.6

mmol/l

—

(3043109) Cytology report of Tissue fine needle aspirate Cyto stain

0.00

0.0

1.0

—

Mortality – FinRegistry

↥

Association

Association between endpoint CD2_INSITU_PENIS_EXALLC and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have CD2_INSITU_PENIS_EXALLC.

N-year risk	Females	Males
1	No data	No data
5	No data	No data
10	No data	No data
15	No data	No data
20	No data	No data

Relationships between endpoints

↥

Index endpoint: CD2_INSITU_PENIS_EXALLC – Carcinoma in situ of penis

GWS hits: -

Endpoint

Case Overlap

Survival Analysis

Genetic Correlations

Genetic Signals

N (Jaccard index)

HR [CI]

rg [CI]

Hits

Coloc Hits

FinRegistry

FinnGen

FinRegistry

FinnGen

Loading data

≡ Risteys

FG R12 + FR

FinnGen R11 + FinRegistry

FinnGen R10 + FinRegistry

FinnGen R10

FinnGen R9

FinnGen R8

FinnGen R7

FinnGen R6

FinnGen R5

FinnGen R4

FinnGen R3

Carcinoma in situ of penis

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

All original rules

Similar endpoints

Case counts by codes

Summary Statistics

-FinRegistry-

Key figures

-FinnGen-

Key figures

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS (R11)

LabWAS

Mortality – FinRegistry

Association

Females

Males

Mortality risk

Relationships between endpoints